source
- Arrowhead’s experimental RNAi drug ARO-MAPT cuts tau protein by 73% in early human trialArrowhead Pharmaceuticals said its experimental RNA interference therapy, ARO-MAPT, lowered the Alzheimer’s‑linked tau protein in a first‑in‑human study of healthy volunteers. The early‑stage tria…
- Gilead invests up to $1.87 B in Vir Biotechnology for three T-cell engagersGilead Sciences announced a licensing agreement with Vir Biotechnology that includes an equity investment and potential milestone payments totalling up to $1.87 billion. The upfront component is $…